ArticleOncoTargets and therapy2026
Glycosylation-Related Gene Signature Identifies MFNG as a Key Driver of Proliferation and Metastasis in Colorectal Cancer.
Article in OncoTargets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) ranks as the third most common malignancy and second leading cause of cancer-related mortality worldwide. Aberrant glycosylation has emerged as a hallmark of cancer, yet systematic analyses of glycosylation-related gene expression patterns and their prognostic implications in CRC remain limited. Methods: We conducted comprehensive analyses of 214 glycosylation-related genes using TCGA and GEO datasets. Differential expression analysis identified significantly altered genes, followed by LASSO Cox regression to construct a four-gene glycosylation-Related Gene Signature (GRGS). We validated the model across multiple independent cohorts and performed functional experiments with MFNG knockdown in CRC cell lines and zebrafish xenograft models. Results: We identified 54 differentially expressed glycosylation-related genes in CRC tissues. The four-gene signature comprising MFNG (manic fringe), UST (uronyl 2-sulfotransferase), SLC35D1 (solute carrier family 35 member D1), and GALNT7 (polypeptide N-acetylgalactosaminyltransferase 7) demonstrated robust prognostic performance across validation cohorts. GRGS-High patients exhibited significantly shorter overall survival and were associated with advanced tumor stages. MFNG emerged as the top predictor, with high expression correlating with poor survival. Functional validation confirmed that MFNG knockdown significantly inhibited CRC cell proliferation, migration, and invasion both in vitro and in vivo. Conclusion: Our study establishes GRGS as a reliable prognostic tool for CRC risk stratification and identifies MFNG as a promising therapeutic target. These findings provide valuable insights into glycosylation-mediated CRC progression and offer potential clinical applications for precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.